Table 2 Clinical characteristics of patients after PSM
Characteristics | Non-HPD | HPD | p value | Method |
|---|---|---|---|---|
N | 216 | 36 | Â | Â |
Gender, N (%) | Â | Â | 0.253 | Chisq test |
 Female | 58 (23.0%) | 13 (5.2%) |  |  |
 Male | 158 (62.7%) | 23 (9.1%) |  |  |
Pathology type, N (%) | Â | Â | 0.112 | Yates' correction |
 Adenocarcinoma | 106 (42.1%) | 22 (8.7%) |  |  |
 Squamous | 55 (21.8%) | 12 (4.8%) |  |  |
 Small Cell Carcinoma | 29 (11.5%) | 2 (0.8%) |  |  |
 Sarcoma | 2 (0.8%) | 0 (0%) |  |  |
 Others | 24 (9.5%) | 0 (0%) |  |  |
Differentiation, N (%) | Â | Â | 0.150 | Yates' correction |
 Low Differentiation | 128 (50.8%) | 18 (7.1%) |  |  |
 Low To Median Differentiation | 30 (11.9%) | 3 (1.2%) |  |  |
 Median Differentiation | 34 (13.5%) | 12 (4.8%) |  |  |
 Median To High Differentiation | 1 (0.4%) | 0 (0) |  |  |
 Unknown | 23 (9.1%) | 3 (1.2%) |  |  |
No gene mutation, N (%) | Â | Â | 0.504 | Chisq test |
 No | 49 (19.4%) | 10 (4.0%) |  |  |
 Yes | 167 (66.3%) | 26 (10.3%) |  |  |
Ki67, N (%) | Â | Â | 0.711 | Yates' correction |
 0–25% | 17 (6.7%) | 3 (1.2%) |  |  |
 26–50% | 20 (7.9%) | 5 (2%) |  |  |
 51–75% | 18 (7.1%) | 1 (0.4%) |  |  |
 76–100% | 19 (7.5%) | 4 (1.6%) |  |  |
 Unknown | 142 (56.3%) | 23 (9.1%) |  |  |
TNM, N (%) | Â | Â | 0.705 | Yates' correction |
 III | 20 (6.7%) | 3 (1.2%) |  |  |
 IV | 194 (77.0%) | 32 (12.7%) |  |  |
 Unknown | 2 (0.8%) | 1 (0.4%) |  |  |
Smoking, N (%) | Â | Â | 0.452 | Yates' correction |
 Never | 103 (40.9%) | 20 (7.9%) |  |  |
 Ever | 76 (30.2%) | 13 (5.2%) |  |  |
 Current | 33 (13.1%) | 2 (0.8%) |  |  |
 Unknown | 4 (1.6%) | 1 (0.4%) |  |  |
Drinking, N (%) | Â | Â | 0.218 | Yates' correction |
 Never | 120 (47.6%) | 22 (8.7%) |  |  |
 Ever | 37 (14.7%) | 9 (3.6%) |  |  |
 Current | 56 (22.2%) | 4 (1.6%) |  |  |
 Unknown | 3 (1.2%) | 1 (0.4%) |  |  |
Family History of Tumor, N (%) | Â | Â | 0.028 | Yates' correction |
 Yes | 61 (24.2%) | 8 (3.2%) |  |  |
 No | 150 (59.5%) | 24 (9.5%) |  |  |
 Unknown | 5 (2.0%) | 4 (1.6%) |  |  |
KPS score, N (%) | Â | Â | 0.948 | Yates' correction |
 10–20 point | 7 (2.8%) | 1 (0.4%) |  |  |
 30–40 point | 2 (0.8%) | 0 (0) |  |  |
 70–80 point | 46 (18.3%) | 9 (3.6%) |  |  |
 90–100 point | 160 (63.5%) | 26 (10.3%) |  |  |
 Unknown | 1 (0.4%) | 0 (0) |  |  |
Combined Chemotherapy, N (%) | Â | Â | 0.181 | Chisq test |
 Yes | 110 (43.7%) | 14 (5.6%) |  |  |
 No | 106 (42.1%) | 22 (8.7%) |  |  |
Combined Antiangiotherapeutics, N (%) | Â | Â | 0.038 | Chisq test |
 No | 157 (62.3%) | 32 (12.7%) |  |  |
 Yes | 59 (23.4%) | 4 (1.6%) |  |  |
Combined Target Therapy,N (%) | Â | Â | 1.000 | Yates' correction |
 No | 210 (83.3%) | 35 (13.9%) |  |  |
 Yes | 6 (2.4%) | 1 (0.4%) |  |  |
Combined Radiotherapy, N (%) | Â | Â | 0.745 | Yates' correction |
 No | 197 (78.2%) | 34 (13.5%) |  |  |
 Yes | 19 (7.5%) | 2 (0.8%) |  |  |
Combined Other Therapy, N (%) | Â | Â | 0.209 | Chisq test |
 No | 84 (33.3%) | 18 (7.1%) |  |  |
 Yes | 132 (52.4%) | 18 (7.1%) |  |  |
Lung Metastasis, N (%) | Â | Â | 0.440 | Chisq test |
 No | 105 (41.7%) | 20 (7.9%) |  |  |
 Yes | 111 (44.0%) | 16 (6.3%) |  |  |
Brain Metastasis, N (%) | Â | Â | 0.245 | Chisq test |
 No | 182 (72.2%) | 33 (13.1%) |  |  |
 Yes | 34 (13.5%) | 3 (1.2%) |  |  |
Bone Metastasis, N (%) | Â | Â | 0.335 | Chisq test |
 No | 151 (59.9%) | 28 (11.1%) |  |  |
 Yes | 65 (25.8%) | 8 (3.2%) |  |  |
Adrenal Metastasis, N (%) | Â | Â | 0.040 | Yates' correction |
 No | 187 (74.2%) | 36 (14.3%) |  |  |
 Yes | 29 (11.5%) | 0 (0) |  |  |
Subcutaneous Metastasis, N (%) | Â | Â | 1.000 | Yates' correction |
 No | 213 (84.5%) | 36 (14.3%) |  |  |
 Yes | 3 (1.2%) | 0 (0) |  |  |
Muscle Metastasis, N (%) | Â | Â | 0.598 | Fisher test |
 No | 210 (83.3%) | 36 (14.3%) |  |  |
 Yes | 6 (2.4%) | 0 (0) |  |  |
Meningeal Metastasis, N (%) | Â | Â | 1.000 | Fisher test |
 No | 215 (85.3%) | 36 (14.3%) |  |  |
 Yes | 1 (0.4%) | 0 (0) |  |  |
Pericardial Metastasis, N (%) | Â | Â | 0.598 | Fisher test |
 No | 210 (83.3%) | 36 (14.3%) |  |  |
 Yes | 6 (2.4%) | 0 (0) |  |  |
Intraabdominal Metastasis, N (%) | Â | Â | 0.849 | Chisq test |
 No | 171 (67.9%) | 29 (11.5%) |  |  |
 Yes | 45 (17.9%) | 7 (2.8%) |  |  |
Pancreatic Metastasis, N (%) | Â | Â | 0.782 | Yates' correction |
 No | 211 (83.7%) | 36 (14.3%) |  |  |
 Yes | 5 (2.0%) | 0 (0) |  |  |
Liver Metastasis, N (%) | Â | Â | 0.169 | Chisq test |
 No | 143 (56.7%) | 28 (11.1%) |  |  |
 Yes | 73 (29.0%) | 8 (3.2%) |  |  |
Non-draining Areas Metastasis, N (%) | Â | Â | 0.323 | Yates' correction |
 No | 209 (82.9%) | 33 (13.1%) |  |  |
 Yes | 7 (2.8%) | 3 (1.2%) |  |  |
Pleural Metastasis, N (%) | Â | Â | 0.366 | Yates' correction |
 No | 197 (78.2%) | 35 (13.9%) |  |  |
 Yes | 19 (7.5%) | 1 (0.4%) |  |  |
 Age, Median (IQR) | 58 (51, 67) | 58 (50.25, 66.25) | 0.773 | Wilcoxon |
 Height, Mean ± Sd | 1.685 ± 0.074 | 1.668 ± 0.079 | 0.225 | T test |
 Weight, Median (IQR) | 63 (56, 71) | 61 (51.75, 70) | 0.309 | Wilcoxon |
 BMI, Median (IQR) | 22.519 (19.794, 24.612) | 21.967 (18.423, 25.025) | 0.755 | Wilcoxon |